Larimar Therapeutics, Inc.
LRMR
$3.58
-$0.31-7.97%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -105.54% | -103.79% | -71.05% | -111.26% | -118.15% |
| Total Depreciation and Amortization | 10.06% | 5.59% | 0.62% | 4.15% | 2.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.96% | 41.67% | -18.03% | -52.19% | -41.11% |
| Change in Net Operating Assets | 662.70% | 1,012.97% | -66.96% | 110.47% | 345.92% |
| Cash from Operations | -59.98% | -65.54% | -114.90% | -139.24% | -111.48% |
| Capital Expenditure | 82.33% | 46.00% | 29.45% | -243.90% | -214.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 218.30% | 180.38% | 144.36% | 98.42% | -353.22% |
| Cash from Investing | 217.48% | 179.75% | 144.09% | 97.98% | -356.01% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -59.75% | -59.72% | -99.96% | -99.96% | 540,623.33% |
| Repurchase of Common Stock | 39.82% | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -59.79% | -59.64% | -99.96% | -100.17% | 539,510.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 809.94% | 1,587.14% | 79.91% | -6,314.01% | 7,647.37% |